Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FDJQ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The award, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract valued at $499.999 billion and extending through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors capable of supplying comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance history across multiple therapeutic categories—including oncology treatments, biologics, vaccines, and specialty pharmaceuticals—demonstrates the company's capability to fulfill the diverse pharmaceutical requirements of the federal military medical system. The Xtandi delivery order exemplifies the routine pharmaceutical procurement facilitated through this strategic contracting vehicle, enabling the Defense Logistics Agency to efficiently procure specialized medications for military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FDJQ2?
SPE2DR26FDJQ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FDJQ2 worth?
The government has obligated $17,021 on SPE2DR26FDJQ2.
Is contract SPE2DR26FDJQ2 an order under another contract?
Yes. SPE2DR26FDJQ2 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJQ2 competed?
The extent of competition for SPE2DR26FDJQ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award